Patient Leaflet Updated 15-Sep-2021 | Ranbaxy (UK) Limited a Sun Pharmaceutical Company
Terlipressin acetate 0.12 mg/ml solution for injection
Terlipressin acetate 0.12 mg/ml solution for injection
terlipressin (as acetate)
1. What Terlipressin acetate 0.12 mg/ml solution for injection is and what it is used for
2. What you need to know before you are given Terlipressin acetate 0.12 mg/ml solution for injection
3. How to use Terlipressin acetate 0.12 mg/ml solution for injection
4. Possible side effects
5. How to store Terlipressin acetate 0.12 mg/ml solution for injection
6. Contents of the pack and other information
Terlipressin acetate 0.12 mg/ml solution for injection is a synthetic pituitary hormone.
Terlipressin acetate 0.12 mg/ml solution for injection is used for treatment of bleeding from dilated veins in the food pipe leading to your stomach (bleeding oesophageal varices).
This medicine will be given to you if you have severe or life-threatening bleeding in your food pipe (oesophagus). It is used under continuous monitoring of your heart and blood circulation.
If you are able to, tell your doctor if you suffer from the conditions shown below:
Terlipressin acetate 0.12 mg/ml solution for injection is not recommended for use in children and adolescents due to insufficient experience.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
Please inform your doctor immediately if you use the following medicines:
Terlipressin acetate 0.12 mg/ml solution for injection should only be used during pregnancy if it is vital to treat your condition. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.
It is not known if Terlipressin acetate 0.12 mg/ml solution for injection is present in breast milk. Therefore the possible effects on your baby are unknown. You should discuss the potential risk to your baby with your doctor.
No studies on the effects on the ability to drive and use machines have been performed. However, if you feel unwell after receiving the injection, do not drive or operate machinery.
This medicinal product contains 15.7 mmol (or 361 mg) sodium per dose. To be taken into consideration by patients on a controlled sodium diet.
This medicine will always be administered to you by your doctor. Please ask your doctor for further information regarding its use.
Adults
Initially 1-2 mg terlipressin acetate (equivalent to 8.5-17 ml of injection solution) is given by injection into your vein. Your dose will depend on your body weight.
After the initial injection, your dose may be reduced to 1 mg terlipressin acetate (equivalent to 8.5 ml of solution), every 4 to 6 hours.
The maximum dose you can receive each day is approximately 120 micrograms/kg body weight.
Elderly
If you are over 70 years of age speak with your doctor before you receive Terlipressin acetate 0.12 mg/ml solution for injection.
Terlipressin acetate 0.12 mg/ml solution for injection should be slowly injected intravenously.
The use is limited to 2 – 3 days, depending on the course of your condition.
You must not have more Terlipressin acetate 0.12 mg/ml solution for injection than the recommended dose. If you are given too much then you may have a rapid increase in your blood pressure, especially if you already suffer with high blood pressure. If this happens then you need another medicine called an alpha blocker (e.g. clonidine) to control your blood pressure.
If you experience lightheadedness, dizziness, or feeling faint, tell your doctor as these could be signs of a low heart rate. This can be treated with a medicine called atropine.
You will be given Terlipressin acetate 0.12 mg/ml solution for injection in hospital under the supervision of your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In very rare cases severe side effects are possible when you are given terlipressin. If you are affected by one of the following side effects, please tell your doctor immediately if you are able to. Your doctor should not give you any more terlipressin.
Severe shortness of breath due to an asthma attack, severe difficulty with or stopping breathing, severe pain in the chest (angina), severe and persistent irregular heartbeats, locally dead skin (necrosis), convulsions (seizure), kidney failure.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the ampoule after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator at 2-8˚C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Terlipressin acetate 0.12 mg/ml solution for injection is a clear, colourless solution for injection without visible particles.
Terlipressin acetate 0.12 mg/ml solution for injection is packed into one carton with 5 ampoules.
This medicinal product is authorised in the Member States of the EEA under the following names:
Denmark: Terlipressinacetat SUN
Germany: Terlipressin SUN 0,1 mg/ml Injektionslösung
Finland: Terlipressin SUN 1 mg injektioneste, liuos
France: Terlipressine SUN 0,12 mg/ml, solution injectable
Italy: Terlipressina SUN 0,1 mg/ml soluzione iniettabile
The Netherlands: Terlipressine SUN 0,1 mg/ml, oplossing voor injectie
Norway: Terlipressin SUN 1 mg injeksjonsvæske, oppløsning
Spain: Terlipresina SUN 1 mg solución inyectable EFG
Sweden: Terlipressin SUN 1 mg injektionsvätska, lösning
United Kingdom: Terlipressin acetate 0.12 mg/ml solution for injection
This leaflet was last revised in June 2021.
5221270
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW, UK
+44 (0) 208 848 5052